Apr 30, 2021 12:19pm
Researchers at Kaiser Permanente wanted to study the predictors of valvular heart disease and looked at whether they could train AI software to spot which patients have valvular heart disease by studying echocardiogram reports. (Kaiser Permanente)(Ted Eytan/CC BY-SA 2.0)
Kaiser Permanente is exploring the use of artificial intelligence to cull through doctors’ medical reports and help identify patients with aortic stenosis, a common heart valve disease, and other chronic health conditions.
As part of ongoing research into the predictors of valvular heart disease, researchers looked at whether they could train AI software to spot which patients have valvular heart disease by studying echocardiogram reports, according to Matthew Solomon, M.D., Ph.D., a physician researcher with the Kaiser Permanente Division of Research and a cardiologist.
People with slightly high blood pressure may need medication
sfgate.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sfgate.com Daily Mail and Mail on Sunday newspapers.
International COVID Registry Finds Inequities in Heart Attack Outcomes Based on Ethnicity
vasculardiseasemanagement.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vasculardiseasemanagement.com Daily Mail and Mail on Sunday newspapers.
In February, Entresto won an expanded indication in heart failure with preserved ejection fraction (HFpEF).
Novartis is banking on a broader label to expand the reach of its blockbuster heart med Entresto, but in patients who ve suffered prior heart attacks, the drug just hit a setback.
In the phase 3 Paradise-MI trial, Entresto missed its primary endpoint to reduce the risk of cardiovascular death and heart failure after an acute myocardial infarction, Novartis quietly revealed in its first-quarter earnings statement. In the study, numerical trends consistently favored the drug against standard of care ramipril, but Entresto fell short of its goal. Novartis says it ll “continue to evaluate the data.”